The development of diffuse panbronchiolitis during the treatment with long-term, low-dose clarithromycin for chronic sinusitis.

Abstract

Diffuse panbronchiolitis (DPB) is a progressive inflammatory airway disease characterized by a chronic cough, copious sputum expectation, dyspnea, and chronic sinusitis. Owing to the long-term treatment of low-dose macrolides, the prognosis has been remarkably improved. However, in some cases, patients are refractory to macrolides, and the subsequent treatment strategies are controversial. We herein present a patient with the onset of DPB during treatment with long-term, low-dose clarithromycin (CAM) for chronic sinusitis who was successfully treated by switching to long-term treatment with normal-dose CAM. We should recognize that DPB may develop in patients with chronic sinusitis despite treatment with a long-term, low-dose macrolide. We also propose that increasing the dose of macrolide may be a useful strategy for treating refractory patients.

• Authors: Masaru Ando, Tomoko Ono, Yuko Usagawa, Hiroki Yoshikawa, Takashi Hirano, Issei Tokimatsu, Jun-Ichi Kadota
• Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (J Infect Chemother) Vol. 25 Issue 2 Pg. 147-150 (Feb 2019) ISSN: 1437-7780 [Electronic] Netherlands
• PMID: 30097373 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2018. Published by Elsevier Ltd.

Chemical References

• Anti-Bacterial Agents
• Clarithromycin

Topics

• Adult
• Anti-Bacterial Agents (adverse effects, therapeutic use)
• Bronchiolitis
• Chronic Disease
• Clarithromycin (adverse effects, therapeutic use)
• Haemophilus Infections
• Humans
• Male
• Sinusitis (drug therapy)